Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

Item
http://www.wikidata.org/entity/Q37850802
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled TrialsDetection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader StudyA systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme.Constitutive Expression of MAP Kinase Phosphatase-1 Confers Multi-drug Resistance in Human Glioblastoma Cells.Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon.
P2860

Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

Item
http://www.wikidata.org/entity/Q37850802
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
@en
Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
@nl
type
label
Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
@en
Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
@nl
prefLabel
Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
@en
Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Irinotecan and bevacizumab in recurrent glioblastoma multiforme
@en
P2093
P2860
P304
P31
P356
10.1517/14656566.2011.566558
P407
P433
P478
P50
P577
P698
P921